<?xml version="1.0" encoding="UTF-8"?>

     <urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
	 
<url>
  <loc>https://www.forxiga.co.uk/</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>1.00</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/chronic-kidney-disease.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/type-2-diabetes.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/heart-failure.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/safety.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/clinical-and-prescribing-details/prescribing-and-dosing.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/clinical-and-prescribing-details/mechanism-of-action.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/clinical-and-prescribing-details/sglt2-inhibitors-in-t2d.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/resources/all-resources.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/resources/dapagliflozin-patient-identification.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
  <loc>https://www.forxiga.co.uk/contact-us.html</loc>
  <lastmod>2024-02-15T12:04:35+00:00</lastmod>
  <priority>0.80</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/resources/resources/videos/Impact_not_treating_renal_complications_of_T2D.html</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url> 
<url>
	<loc>https://www.forxiga.co.uk/resources/resources/videos/pardeep-jhund-simplifying-the-management-of-hf.html</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url> 
<url>
	<loc>https://www.forxiga.co.uk/resources/resources/videos/professor-james-burton-michael-story.html</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url> 
<url>
	<loc>https://www.forxiga.co.uk/resources/resources/videos/yassir-javaid-ng28-guidelines.html</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url> 
<url>
	<loc>https://www.forxiga.co.uk/resources/resources/videos/yassir-javaid-t2d.html</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>  
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/SGLT2i_dosing_considerations_according_to_eGFR_when_treating_T2D_HF_or_CKD_April_2023_A4.pdf</loc>
	<lastmod>2023-08-23T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/forxiga-initiation-checklist-for-hcp.pdf</loc>
	<lastmod>2023-08-23T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/CKD_with_T2D.pdf</loc>
	<lastmod>2023-08-23T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/HF_with_T2D.pdf</loc>
	<lastmod>2023-08-23T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/Forxiga-T2D-Patient-Info-Booklet.pdf</loc>
	<lastmod>2023-08-23T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/Forxiga-Formulary-Support-Pack-for-the-treatment-of-symptomatic-chronic-Heart-Failure.pdf</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/HF_without_T2D.pdf</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/CKD_without_T2D.pdf</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>
<url>
	<loc>https://www.forxiga.co.uk/content/dam/intelligentcontent/brands/forxiga-uk/en/resources/pdf/Forxiga-Sick-Day-Rules-digital-version.pdf</loc>
	<lastmod>2024-02-18T16:30:46+01:00</lastmod>
	<priority>1.0</priority>
</url>  
</urlset>